ẢNH HƯỞNG TÌNH TRẠNG VIÊM GAN VIRUS ĐẾN KẾT QUẢ ĐIỀU TRỊ SORAFENIB TRÊN BỆNH NHÂN UNG THƯ BIỂU MÔ TẾ BÀO GAN

Abstract

Sorafenib is approved for first line treatment of hepatocellular carcinoma (HCC) without indications of local intervention treatment. Some study have been done to determine the prognostic factors to treatment outcomes, but until now there is no consensus, in which hepatitis viral infection is controversial factor. The study was done to assess the effect of hepatitis vỉal infection on the results of sorafenib treatment in patients with HCC. Descriptive study on 110 HCC patients treatted with sorafenib in K Hospital and Hanoi Medical University Hospital from January 2010 to November 2018. The rate of hepatitis B virus (HBV) 75.5%, hepatitis C virus (HCV) 3.6%, co-infection with hepatitis B and C 0.9%, no hepatitis viral infection 20%. The rate of disease control in the group of HBV, HCV, co-infection with HBV-HCV were 55.4%, 50.0%, 100%, 72.7% (p>0,05), respectively. Median progression free survival (PFS) in the HBV, HCV, HBV- HCVco-infection, and no hepatitis viral infection were 4.4 months, 2.1 months, 5.1 months, and 6.7 months, respectively (p>0,05). Median overal survival (OS) in the HBV, HCV, HBV-HCV co-infection, and non hepatitis viral infection were 5.9 months, 2.5 months, 17.1 months, 13.1 months, respectively (p>0,05). In multivariate analysis, HBV was an independent predictor of OS, HBV increased the risk of death by 2.5 times compared with no HBV (HR = 2,542, 95% CI: 1,327- 4,870).